M&A IP Due Diligence. Evidence Before the Decision.

M&A IP due diligence is the deal-timeline review that establishes what an acquisition target actually owns, what that intellectual property is worth, and what about it could break the investment thesis after close. In a market where intangible assets now account for roughly 92% of the S&P 500’s value, the patents, trademarks and trade secrets on the target’s books are frequently the thing being bought — yet they are the assets least visible on a balance sheet and the easiest to over-value in a data room. We read the portfolio against the primary record so the number you underwrite is the number you can defend.

What M&A IP Due Diligence Actually Answers

M&A IP due diligence is not a legal formality bolted onto the end of a deal. It is a structured read of the target’s intellectual property that answers three questions a buyer cannot afford to guess at: does the target own what it claims to own, is that ownership clean and unencumbered, and is the IP worth what the purchase price assumes. Everything else in the workstream — the inventory, the title search, the valuation, the red-flag register — exists to answer one of those three.

The reason it sits on the critical path is that IP is where the deal thesis and the balance sheet diverge most sharply. A target can present a confident list of patents in a data room while the underlying rights sit with a founder, a former employer, a university or a contractor who never assigned them. The list looks like an asset; the title tells you whether it is one. Good diligence closes that gap before the price is fixed, not after the wire clears.

Three teams rely on the output. Corporate-development and deal leads use it to test the acquisition thesis and set walk-away conditions. Transaction counsel uses it to draft representations, warranties and the specific indemnities that a title defect demands. PE and VC investors use it to underwrite the intangible value that increasingly is the company. The deliverable is written to be handed to all three and acted on inside a deal calendar.

Why IP Now Sets the Deal Price

The case for taking IP diligence seriously is written into the market’s own accounting. Ocean Tomo’s Intangible Asset Market Value Study puts intangible assets at roughly 92% of the total market value of the S&P 500 — an inversion from 1975, when tangible assets such as property, plant and inventory made up 83% of that value. In half a century the balance of what a company is worth has migrated from what you can touch to what you can only read off a register.

For an acquirer that changes what diligence has to interrogate. When the majority of enterprise value is intangible, a review that stops at audited financials and physical assets is auditing the wrong 8%. The patents, brands, software and trade secrets are the consideration, and their condition — owned outright, licensed in, jointly held, encumbered or merely asserted — is what determines whether the multiple you are paying is real.

This is also why IP diligence and IP valuation belong in the same workstream. A patent family means little as a line item; it means a great deal once you know the products it reads on, the revenue it protects, the term it has left and the rivals it excludes. The valuation range is only as trustworthy as the ownership and encumbrance picture underneath it, which is exactly what the rest of the diligence establishes.

Chain of Title: The Risk That Voids What You Paid For

The single most expensive defect in an IP portfolio is not a weak patent — it is a broken chain of title, where the rights the target is selling do not cleanly belong to the entity selling them. Under 35 U.S.C. § 261, a patent assignment is void as against a later good-faith purchaser for value unless it is recorded at the USPTO within three months of execution, or before that later purchase. In other words, an unrecorded or late-recorded assignment can be cut off by someone who recorded first, even if their assignment came second.

In a deal context that statute turns a paperwork lapse into a valuation problem. If an inventor never assigned, if a subsidiary reorganisation moved patents without recording the transfer, or if a startup’s founder holds rights the company only assumes it owns, the acquirer can find itself paying for assets the target cannot actually convey. Verifying chain of title means walking every family from the inventor’s original assignment through each corporate transfer to the entity signing the deal, and reconciling it against the recorded USPTO record rather than the target’s own schedule.

The same discipline extends beyond patents. Trademark ownership has to match the goods and services actually sold and the entity that will hold them post-close. Copyright and software built by contractors needs written assignment or a valid work-made-for-hire basis, not an assumption. Trade secrets are only protected if the target took reasonable steps to keep them secret — a fact that has to be evidenced, not asserted. Each of these is a place where a confident data-room schedule and the enforceable legal reality quietly part company.

Building the Target’s Portfolio Inventory

Diligence starts by rebuilding the portfolio from the primary record rather than accepting the target’s spreadsheet at face value. We pull the live and pending patent families, registered and pending trademarks, recorded design rights and the material trade secrets, and we tie each asset to the exact legal entity on the filing — because in a group with multiple subsidiaries, the entity being acquired is not always the entity that owns the IP.

Assignee normalisation is where a rebuilt inventory beats a handed-over list. One owner filing under three names, a dormant holding company that never transferred its rights, or an asset quietly sitting with a foreign parent all surface here and nowhere else. The inventory also captures status and maintenance: a patent lapsed for unpaid fees, an application abandoned mid-prosecution, or a mark vulnerable for non-use is worth nothing on the day of close regardless of how it reads on the schedule.

The finished inventory is the spine of the whole engagement. Chain-of-title verification runs against it, the valuation range is built on it, and the red-flag register hangs off it. Get the inventory wrong — miss a family, misattribute an owner, overlook a lapsed right — and every downstream conclusion inherits the error, which is precisely why we anchor it in the register and not the data room.

Turning the Portfolio Into a Defensible Number

Once ownership is clean, the question becomes what the IP is actually worth to this buyer, for this thesis. A defensible valuation range does not treat every patent equally; it separates the families that read on real revenue and block real competitors from the long tail of filings that inflate a count without protecting anything. The first group carries the value; the second is maintenance cost dressed up as an asset.

We frame the range around the deal rationale. In an acqui-hire the value sits in people and know-how, and the patents are defensive; in a technology buy the core families are the entire point, and their term, geographic coverage and claim breadth drive the number; in a roll-up the question is whether the target’s IP is duplicative of what the acquirer already holds or genuinely additive. The same portfolio can be worth materially different amounts depending on which of those the buyer is doing.

Crucially, the valuation is delivered as a range with its assumptions exposed, not a single confident figure. Remaining patent term, the strength of the independent claims, encumbrances such as licences-out or standard-essential commitments, and the competitive position each move the number, and a buyer negotiating a price needs to see which lever moved it. That transparency is what lets the figure survive an investment committee instead of merely decorating a deck.

Red Flags That Break the Deal Thesis

Some findings do not adjust the price — they change whether the deal makes sense at all. The red-flag register is the part of M&A IP due diligence that hunts for those. A licence-out that the target signed years ago can mean the ‘exclusive’ technology you are buying is already in a competitor’s hands. A lien or security interest recorded against the patents means a lender, not the seller, has first claim on the assets. A standard-essential patent carries FRAND commitments that travel with the asset and cap what you can extract from it.

Litigation and challenge exposure belong on the same register. Pending or threatened infringement suits, inter partes review petitions against the target’s key patents, or an opposition against a flagship trademark can each hollow out the asset you are underwriting. So can a freedom-to-operate problem running the other way — where the target’s own product may infringe a third party’s live claims, importing a liability the acquirer inherits at close.

The register’s job is to grade each of these by how it hits the thesis: a price adjustment, a specific indemnity, a condition to closing, or a reason to walk. Presented that way, IP diligence stops being a box-ticking legal exercise and becomes a direct input to the negotiation — the difference between discovering an encumbrance across the table and discovering it a year after the wire has cleared.

How the Diligence Fits the Deal Timeline

IP diligence only helps if it lands when the deal team can still act on it. We scope the work to the calendar: a fast, targeted screen in the exclusivity or LOI phase to confirm the core assets are real and clean before serious money is spent, then a deeper inventory, title and valuation pass through the confirmatory-diligence window as the definitive agreement is drafted. Findings feed straight into the representations and warranties and the specific indemnities counsel builds around any title or encumbrance issue.

Sequencing matters because IP defects are cheapest to fix before signing. A missing assignment can often be cured if it is found while the inventor is still cooperative and the leverage still sits with the buyer; the same defect found post-close becomes litigation. Framing the diligence around the timeline — screen early, verify deeply, price the residual risk — is what keeps a title problem from becoming a purchase-price dispute.

The method also travels beyond the buy side. A seller running the same review before going to market — a vendor or sell-side IP diligence — finds and cures its own title gaps in advance, and walks into the data room able to defend both the inventory and the price. Either way, the discipline is the same as our wider IP due diligence in mergers workflow: rebuild from the record, verify the title, price the risk.

How to Brief an M&A IP Due Diligence Review

The sharper the brief, the more useful the review. Tell us the deal type — technology buy, acqui-hire, roll-up or carve-out — because the same portfolio is worth different things under each, and the diligence is scoped accordingly. Name the assets the thesis actually depends on, the geographies that matter, and the point in the timeline you are at, so the depth matches whether you need an early screen or a confirmatory deep dive.

From there we rebuild the portfolio inventory from the primary record, verify chain of title against the USPTO assignment database, build the valuation range around your rationale, and return the red-flag register graded for how each finding hits the deal. The specific checks smart buyers demand are the same ones we run as standard, documented so counsel can draft against them.

Because an M&A IP due diligence report is only as good as the record behind it, every conclusion is anchored in the primary filing and assignment data and cited — so the review holds up in front of an investment committee, a lender or, if it comes to it, the other side’s counsel in a post-close dispute.

What You Receive

• A target portfolio inventory — every patent, application, mark and material trade secret, mapped to the entity that files it
• Chain-of-title verification against the USPTO assignment record, flagging every broken or unrecorded link
• A defensible valuation range for the IP, tied to the deal rationale rather than book value
• A deal-risk red-flag register: encumbrances, licences, liens, standard-essential commitments and litigation exposure
• A primary-source evidence pack that survives an investment-committee or lender review

Data Sources & References

This analysis draws on primary patent and market data:

• Ocean Tomo Intangible Asset Market Value Study — The measure that intangible assets now make up roughly 92% of S&P 500 market value, up from 17% in 1975.
• 35 U.S.C. § 261 — Ownership; assignment — The statute making an unrecorded patent assignment void against a later bona fide purchaser unless recorded within three months.
• USPTO Patent Assignment Search — The public recorded-assignment database used to verify chain of title against a target's own schedule.
• USPTO Manual of Patent Examining Procedure, Ch. 300 (Ownership and Assignment) — The USPTO rules governing recordation and the effect of assignments relied on in title verification.

Request M&A IP Due Diligence

Tell us the target and the deal thesis, and we will verify what it owns, what it is worth, and what could break the deal.

Related PerspireIP work: IP Valuation · IP Due Diligence in Mergers · IP Due Diligence Services: the checks buyers demand.

Frequently Asked Questions